Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes (LymphoEnergy)
Parkinson's Disease, Amyotrophic Lateral Sclerosis, Oxidative Stress
About this trial
This is an interventional basic science trial for Parkinson's Disease focused on measuring Parkinson's disease, Amyotrophic lateral sclerosis, Peripheral blood mononuclear cells, ex vivo model for oxidative stress, iron metabolism and chelation
Eligibility Criteria
Inclusion Criteria:
- Parkinson's disease according to Movement Disorders Society criteria
- Amyotrophic Lateral Sclerosis according to El escorial criteria
- Age and sex matched healthy controls
Exclusion Criteria:
- Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)
Sites / Locations
- Hôpital Roger Salengro, CHRU de Lille
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Parkinson's disease
Amyotrophic lateral sclerosis
healthy age and sex matched controls
ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment